暴涨116%!映恩生物正式登陆港交所4月15日,ADC明星企业映恩生物正式登陆港交所,全球发售股份定价为每股94.6港元,开盘价为181港元,截至收盘,映恩生物每股报205港元,大涨116%,总市值约170.5亿港元。映恩生物拥有自主研发的两款核心产品,即DB-1303/BNT323(一款靶向HER2癌症包括子宫内膜癌及乳腺癌的HER2ADC候选药物);以及DB-1311/BNT324(一款靶向...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.